
















GENOMIC
IMPRINTING

GENE
METHYLATION

METHYLATION
LEADS TO SILENCING
GAIN OF SILENCING
WITH TRANSCRIPTIONAL
SILENCING

MICROSATELLITES
& GENE
MAPPING

DI NUCLEOTIDE
REPEATS

LINEAR
& SINES

SATELLITE DNA

REPEAT
SEQUENCES

UNIQUE DNA
SEQUENCES

MITOCHONDRIA

EUKARYOTIC
GENOME

INFORMATION

PROTEOME

KARYOTYPE ANALYSIS

OVERVIEW

ORGANIZATION

PHYSICAL

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

GENOMICS

FUNCTIONAL
EPIGENETICS
CHROMATIN
REMODELING
COMPLEXES
HAT → TRANSCRIPTION
HDAC → SILENCING
HISTONE MODIFICATION
BY ACETYLATION
LYSINE
RESIDUES
METHYLATION
& TISSUE SPECIFIC
UNUSUAL
STYL
REPRESENT
STABILITY
IN THE

HISTONE CORE, ORIGIN
REPLICATION,
& ENABLING

DNA
BUILDING BLOCKS
TO
SMALL
HISTONES
PROT
SIDE CHAINS
AA

JUST HOW
MUCH
DNA
IS THERE?

DNA PACKAGING REQUIRES
HISTONE MODIFICATION

REVERSIBLE

EC TRANSCRIPTIONAL
ACTIVITY

EC TRANSCRIPTIONAL
ACTIVITY

EC TRANSCRIPTIONAL
ACTIVITY

EC TRANSCRIPTIONAL
ACTIVITY

EC TRANSCRIPTIONAL
ACTIVITY

EC TRANSCRIPTIONAL
ACTIVITY

EC TRANSCRIPTIONAL
ACTIVITY


EC TRANSCRIPTIONAL
ACTIVITY


EC TRANSCRIPTIONAL
ACTIVITY


EC TRANSCRIPTIONAL
ACTIVITY


EC TRANSCRIPTIONAL
ACTIVITY


EC TRANSCRIPTIONAL
ACTIVITY











1/2 LIFE
P
DETEN NUMERO

A thorough & AA
revision

V. P. GERMANO
NEW YORK
d's on the way
during
the
winter
1960

CUV
APP:
→ &
NUMBER
DISEASES

IMP for
Governing
AA
E
owned
SMEs

Lower 1/2 lives

Ans: $P \in$
not worry of
Ance know down
of $P \rightarrow$ strength
per while
returning the
visibility

PROTEIN
DEGRADATION

ATP DEF

PROTEOSOMAL

Ubiquitin

PROTECTED SOME

SHORTEN
1/2 LIVES

napisany


SUBSTRATES
FOR DEGRADATION

STEPS


P-6642-1010


22

run 1 step



~~LEARNING~~
~~ONE~~





ORALLY ADMIN DRUGS
MUST PERMEATE
EPIT OF INT MEM BR
IN ORDER TO ENTER CIRC

EPIT BARRIER

000004

BBB
RESTRICTS
ENTRY OF
DRUGS
TO CNS

FREE DRUG
CROSSING
INT EPIT

DRUG TRANSPORT

OVERVIEW

IDENTIFIED
IN MANY

CLASSES
OF TRANSPORTERS

ACTIVE
MANY DRUGS

PRIMARY
OR SECONDARY

NB WHILE PASSIVE DIFFUSION
HAS LONG BEEN
DEEMED AS A
MECHANISM OF
DRUG T
PM = BARRIER TO FREE DIF

CLASS BASED ON SEQUENCE
SIMILARITIES

DRUGS

DRUGS
DESIGNED
TO INHIBIT
OR KILL THEM
SUCH AS CANCER
EXPOSING
WOUND AGENTS


DRUGS
&
XENOBIOTIC


ABC B1 or
P-GP
MDR

14
ABC
TO INHIBIT
ASSOCIATE

40 ORGANIC
COT
MIT
ORGANIC
IOT
24 SOLUTE
SLCs
PEPT
ACEI
ORGANIC
TRANSPORT
POLYPHOS
OATP

CAN ADD:
MANY OTHER
TYPE KINASES





03 must & affect
2 cl in mi 2017

time $\Rightarrow$
ACCⁿ G2 &
on ACT & no comp $\hookrightarrow$

es

Antibiotics

ANTI MONOPOLY

④ SPEC OR NON - ACTION

ATM / ATM IN G1/G2
CHECKPOINT NEBULAN

BRCA1

TA 47

SENSE &
RESPOND
TO SPEED
DATA DAM KIMAKI

PRODUCE $G_2 \rightarrow M$
 GNT BY
 cdc 25C
 PHOSPHATASE
 & CDK1

ATM
ATM

CDK25C
PHOSPHATASE
CDK1
INHIBIT
G2 M TRANSITION

can App:
HPV, cervical cancer
& TS

153 CNT OF 4 FATE
FOLLOWING DNA DAM

RTS ACTIVATION
OF TRANSCRIPTION
OF SURVIVAL GENES

REDUCES
BALANCE
BETWEEN
DIFF. GROUPS
+ HOMEOSTASIS

SENESCENT

SPEC MADE & DESIGNATED
ING PARTIC POINTS

21

$(\phi \rightarrow \text{Func})$

POINT
DERIVING
AK
en2
paving
through
window
youth
mining
of
Stevens

CyCln-CDK

PROGME^N
THROUG
S ERTF (A) requires
CYCLOW (A) OF
SPR CDKS

RESTING &
Actively
cycling &

REGULAR
(ϕ) $\uparrow$ $\downarrow$ ϕ

REGULATORS

QUESTION

CH

SPEED
EXPENSE
CUTTING &
COST

CDHS

RESERVE POINT G

Судан-СДКФ

TSP ⊖

MUTUAL → HAN
MAN

SAFETY HAN
PARENT ACC
ONA G

HECKPOINT

S PHASE CP
GUT MUTIN
BY 0
R
B

PROBING
THROUGH
CYCLING (C) OF
SPEC CDN

ase
tar

P/kip
INK4A
CDK
F
DAY-

Handwritten notes on a sticky note:

- Quand
- on a
- indur
- can ↑ ch
- 121

RESTING & ACTIVELY CYCLING

